Phase 2b, randomized, double‐blind 12‐week studies of TZP ‐102, a ghrelin receptor agonist for diabetic gastroparesis
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: TZP ‐102, a potent, oral, ghrelin receptor agonist, improved diabetic gastroparesis symptoms in Phase 2a. Methods: Patients with type 1 or 2 diabetes, delayed gastric half‐emptying (T 1/2 ), and ≥3 months gastroparesis symptoms randomized 1 : 1 : 1 to double‐blind placebo, 10‐mg, or 20‐mg TZP ‐102 once daily for 12 weeks (Study TZP ‐102‐ CL ‐G003). Study TZP ‐102‐ CL ‐G004 patients randomized 1 : 1 to 10‐mg TZP ‐102:placebo three‐times‐daily. Primary endpoint was change‐from‐baseline through Weeks 11–12 in Daily Diary of Gastroparesis Symptoms Questionnaire ( GSDD ) via electronic Patient Recorded Outcome device: worst severity of nausea, early satiety, bloating, and upper abdominal pain in 24 h (0 = none‐to‐5 = very severe). GSDD Composite Score for eligibility was ≥2.5 (Day‐14‐to‐baseline). Patient Overall Treatment Evaluation ( OTE ) provided an anchor‐based minimal clinically important difference ( MCID ) for GSDD Composite Score. Key Results: Study TZP ‐102‐ CL ‐G003 enrolled 201 outpatients: females 72%; Caucasians 87%; type 2 diabetes 61%; insulin‐dependent 65%; age mean ± SD 53 ± 11.3 years; HbA1c 7.8 ± 1.5%; GCSI 3.4 ± 0.7; GSDD Composite 3.6 ± 0.6; gastric T 1/2 131 ± 32 min; n = 69 (10‐mg), n = 66 (20‐mg), n = 66 (placebo). Primary endpoint ( GSDD ): significant improvement in all arms, although not for TZP ‐102 vs placebo: mean change‐from‐baseline −1.7, −1.4, −1.5 (10‐mg, 20‐mg, placebo); Gastroparesis Cardinal Symptom Index −1.8, −1.6, −1.5, respectively. The OTE (all patients) at Week‐12 was: Patient 3.7 ± 3.2 and Physician 3.6 ± 3.0 with median score for both of 5.0 = important on scale of improvement; individual MCID was 1.61 and 0.94 for group analyses, greater than expected. Study TZP ‐102‐ CL ‐G004 with similar demographic/disease characteristics was prematurely terminated for efficacy futility (n = 64 with Week‐4 assessments). Conclusions & Inferences: Efficacy of TZP ‐102 was not demonstrated compared with placebo in diabetic gastroparesis; however, there was substantial symptom improvement in all arms ( ClinicalTrials.gov NCT01452815/NCT01664637).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
Kaptchuk, T. J., Kelley, J. M., Conboy, L. A., Davis, R. B., Kerr, C. E., Jacobson, E. E., Kirsch, I., Schyner, R. N., Nam, B. H., Nguyen, L. T., et al. (2008) · BMJ · doi:10.1136/bmj.39524.439618.25 · Cited by 1,196
Self-citationClinical Guideline: Management of Gastroparesis
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.373 · Cited by 1,149
Soykan, I., Sivri, B., Sarosiek, I., Kiernan, B., & Mccallum, R. W. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1026665728213 · Cited by 575
Self-citationJung, H., Choung, R. S., Locke, G. R., Schleck, C. D., Zinsmeister, A. R., Szarka, L. A., Mullan, B., & Talley, N. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.12.047 · Cited by 571
Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000021689.86296.e4 · Cited by 418
Ghrelin stimulates gastric emptying and hunger in normal-weight humans
Levin, F., Edholm, T., Schmidt, P. T., Grybäck, P., Jacobsson, H., Degerblad, M., Höybye, C., Holst, J. J., Rehfeld, J. F., Hellström, P. M., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2638 · Cited by 313
Gastric emptying in diabetes: clinical significance and treatment
Horowitz, M., O’Donovan, D., Jones, K. L., Feinle, C., Rayner, C. K., & Samsom, M. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00658.x · Cited by 308
Szarka, L. A., Camilleri, M., Vella, A., Burton, D., Baxter, K., Simonson, J., & Zinsmeister, A. R. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.01.009 · Cited by 209
Placebo responses in patients with gastrointestinal disorders
Musial, F. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i25.3425 · Cited by 70
Cited by
Gastrointestinal Dysfunction in Parkinson’s Disease
Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E., & Pfeiffer, R. F. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00007-1 · Cited by 1,016
Bharucha, A. E., Kudva, Y. C., & Prichard, D. O. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00161 · Cited by 252
Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study
Carbone, F., Van den Houte, K., Clevers, E., Andrews, C. N., Papathanasopoulos, A., Holvoet, L., Van Oudenhove, L., Caenepeel, P., Arts, J., Vanuytsel, T., et al. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000304 · Cited by 206
Outcomes and Factors Associated With Reduced Symptoms in Patients With Gastroparesis
Pasricha, P. J., Yates, K. P., Nguyen, L., Clarke, J., Abell, T. L., Farrugia, G., Hasler, W. L., Koch, K. L., Snape, W. J., McCallum, R. W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.008 · Cited by 143
Self-citationVosoughi, K., Ichkhanian, Y., Benias, P., Miller, L., Aadam, A. A., Triggs, J. R., Law, R., Hasler, W., Bowers, N., Chaves, D., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-322756 · Cited by 128
Efficacy and Safety of Drugs for Gastroparesis: Systematic Review and Network Meta-analysis
Ingrosso, M. R., Camilleri, M., Tack, J., Ianiro, G., Black, C. J., & Ford, A. C. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.12.014 · Cited by 53
Petri, M., Singh, I., Baker, C., Underkofler, C., & Rasouli, N. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107733 · Cited by 50
Stievenard, A., Méquinion, M., Andrews, Z. B., Destée, A., Chartier-Harlin, M.-C., Viltart, O., & Vanbesien-Mailliot, C. C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.021 · Cited by 39
Time trends in gastroparesis treatment
Dudekula, A., Rahim, S., & Bielefeldt, K. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3369-y · Cited by 21
Metadata
- Authors
- McCallum, R. W., Lembo, A., Esfandyari, T., Bhandari, B. R., Ejskjaer, N., Cosentino, C., Helton, N., Mondou, E., Quinn, J., Rousseau, F., & The TZP‐102 Phase 2b Study Group
- Venue
- Neurogastroenterology & Motility
- Publisher
- Wiley
- Published
- 2013-07-15
- Volume
- 25
- Issue
- 11
- Pages
- e705-17
- ISSN
- 1350-1925 (ISSN-L)
- 1365-2982
- OpenAlex
- W2087955556
- Cited by
- 101
- References
- 10
- FWCI
- 13.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.